Kits and enzymes will lead CRISPR and Cas gene sales through 2036 with 41.3% of the product type segment in 2026. The market was valued at USD 4.1 million in 2025 and is expected to be worth USD 47.73 million by 2036, creating an incremental opportunity of USD 42.6 million.